Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its inclusion in the NASDAQ Biotechnology Index, effective December 20, 2021. This index encompasses biotechnology and pharmaceutical companies meeting specific eligibility criteria, including trading volume and market capitalization. This recognition highlights Sensei's position in the biotechnology sector as it pursues next-generation cancer therapeutics through its innovative TMAb™ and ImmunoPhage™ platforms. The company is advancing its product pipeline, including the antibody SNS-101 and ImmunoPhage cocktail SNS-401-NG for treating cancer.
Sensei Biotherapeutics (NASDAQ: SNSE) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. CEO John Celebi and SVP Erin Colgan will engage in a pre-recorded fireside chat, available for streaming starting November 22, 2021, at 10:00 AM ET on the company’s website. This event highlights Sensei’s innovative immunotherapy approaches, including its TMAb™ and ImmunoPhage™ platforms, focusing on cancer treatments like SNS-101 and the preclinical SNS-401-NG targeting Merkel Cell Carcinoma.
Sensei Biotherapeutics (NASDAQ: SNSE) announced promising preclinical data for its anti-VISTA product candidate, SNS-101. This monoclonal antibody selectively binds to the active form of VISTA in low pH tumor environments, enhancing immune response. Key findings include SNS-101's high affinity and selectivity (~600-fold) for low pH conditions and improved anti-tumor activity when combined with anti-PD-1 therapy. The company is actively pursuing IND-enabling studies and will present findings at the SITC 2021 meeting. A virtual symposium on VISTA's potential will occur on November 16.
SNS-101, a novel tumor-selective anti-VISTA antibody candidate, has been identified by Sensei Biotherapeutics, aimed at overcoming resistance to cancer therapies. Its preclinical data will be presented at the Society for Immunotherapy of Cancer’s annual meeting. As of September 30, 2021, the company reported $156.7 million in cash, ensuring its operational runway through the first half of 2024. R&D expenses increased to $6.4 million, while net loss widened to $9.7 million compared to $5.4 million in Q3 2020. Sensei is progressing with its TMAb platform and anticipates further updates on the ImmunoPhage platform.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on November 9, 2021, at 10:00 a.m. EST. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 90 days afterward. Sensei focuses on developing next-generation immunotherapies for cancer, leveraging its unique TMAb™ and ImmunoPhage™ platforms, including the therapeutic candidate SNS-101 targeting immune checkpoint VISTA and the ImmunoPhage cocktail SNS-401-NG for Merkel Cell Carcinoma.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its presentation of preclinical data for its anti-VISTA candidate, SNS-101, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 10-14, 2021. The data will mark the first scientific presentation from Sensei's TMAb platform, which aims to enhance immune checkpoint therapies through tumor microenvironment selectivity. SNS-101 targets VISTA, a crucial immune checkpoint, to potentially boost anti-cancer immune responses while minimizing side effects.
Sensei Biotherapeutics (NASDAQ: SNSE) reported financial results for Q2 2021, highlighting significant developments in its SNS-VISTA program, which showed notable anti-tumor activity. The company aims to select a lead candidate and begin IND-enabling studies by year-end 2021. As of June 30, 2021, Sensei maintained a strong cash position of $162.5 million, expected to fund operations into 2024. However, the company experienced increased R&D expenses of $5.9 million and a net loss of $9.8 million, reflecting higher operational costs.
Sensei Biotherapeutics (NASDAQ: SNSE) announced the appointment of Kristian Humer as an independent director, effective July 30, 2021. Humer, who joins from Viridian Therapeutics, brings over 20 years of experience in life sciences investment banking. The company’s CEO, John Celebi, expressed confidence in Humer's expertise to guide the firm through its growth phase as a public company. Sensei Biotherapeutics is focused on developing next-generation cancer immunotherapies, leveraging innovative platforms such as ImmunoPhage and TMAb.
Sensei Biotherapeutics is shifting its focus towards developing next-generation phage product candidates, including SNS-401-NG and SNS-VISTA, while discontinuing the SNS-301 program due to suboptimal clinical findings. The decision was driven by an analysis that revealed insufficient T-cell activation. This strategic pivot extends the company's cash runway into the first half of 2024, supporting ongoing operations. Sensei plans to initiate IND-enabling studies for SNS-401-NG by late 2022 and share comprehensive SNS-301 data at a future scientific conference.
Sensei Biotherapeutics reported promising results from its Phase 1/2 trial of SNS-301, an investigational therapy for advanced squamous cell carcinoma of the head and neck. Data shows that SNS-301 combined with pembrolizumab demonstrated a favorable safety profile and a potential for durable tumor responses. Notably, one patient experienced a 71% tumor reduction lasting 11 months. The company expects to provide updated data, including frontline therapy results, by year-end, enhancing the understanding of its proprietary ImmunoPhage platform.